Viewing StudyNCT00001096



Ignite Creation Date: 2024-05-05 @ 11:21 AM
Last Modification Date: 2024-10-26 @ 9:02 AM
Study NCT ID: NCT00001096
Status: COMPLETED
Last Update Posted: 2021-11-04
First Post: 1999-11-02

Brief Title: A Phase I Multicenter Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX BE HIV-1 MN rgp120A244 rgp120 in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Organization: National Institute of Allergy and Infectious Diseases NIAID

Conditions & Keywords Data

Conditions:
Name
HIV Infections
Keywords:
Name View
Vaccines Synthetic View
HIV Antibodies View
HIV Antigens View
HIV-1 View
Adjuvants Immunologic View
AIDS Vaccines View
T-Lymphocytes Cytotoxic View
HIV Seronegativity View
HIV Envelope Protein gp120 View
Alum Compounds View
HIV Preventive Vaccine View